Qbtech Launches Breakthrough Product

STOCKHOLM, April 11, 2016 /PRNewswire/ --

The US Food and Drug Administration (FDA) has cleared the ADHD test - QbCheck - developed by the Swedish company Qbtech to aid in the assessment and evaluation of treatment interventions in patients with ADHD. QbCheck is an online test that provides objective and unbiased decision-making support when diagnosing and treating ADHD in children, adolescents and adults. QbCheck is the only online ADHD test in the world cleared by the FDA as well as CE marked for this usage.

Traditionally, a clinical interview and subjective information from various rating scales have been the clinical standard. This process is complex, involves administrative costs for the clinic and can extend the time to evaluate if treatment is working.  A further limitation is that such evaluations carry significant risk for biased feedback.^[i]  QbCheck provides unbiased and objective outcome measurements that can be utilized quickly and easily so that professionals are informed to act in ADHD. The new ADHD Total Symptom Score also simplifies the process to identify the test taker's likelihood of having ADHD like symptoms- a feature designed to support improved decision making. QbCheck is based on the same proven technology as QbTest - a test performed by approximately 250 000 patients in Europe and the US.

- QbCheck is the first objective online ADHD test in the world to be cleared by the FDA. Being online means that new customer groups including smaller clinics, schools, rural providers and other qualified professionals can provide their patients and clients access to the latest medical technology - a big step to transform the management of ADHD, explains Carl Reuterskiöld, CEO of Qbtech.

- Worldwide, the new customer groups like primary care providers are responsible for about 75% of all ADHD care. Even before launch we have seen a fantastic level of interest from hundreds of new professionals keen to use QbCheck to improve their referral process and management of ADHD. An initial launch in the UK in April will be followed by other countries during the summer and autumn, says Tony Doyle, Commercial Director of Qbtech.

A Better View of ADHD 

QbCheck and QbTest make it easier to identify, rule out and monitor ADHD by providing an unbiased view of the patient's symptoms. By adding QbCheck and QbTest to the clinical pathway, studies show that you can improve diagnostic accuracy, reduce the risk of unidentified ADHD and help to identify patients not responding to treatment.^{[ii], [iii]}

QbCheck measures the three core signs of ADHD - hyperactivity, inattention and impulsivity. QbCheck is a online test that combines a test of sustained attention with a movement analysis based on face tracking technology. The test taker's results are compared with norm data from groups of people of the same sex and age with and without ADHD.

Qbtech AB is a privately owned Swedish company founded in 2002. Qbtech is engaged in developing solutions and products for improving the diagnosis, treatment and follow-up of patients with neuropsychiatric disorders. Qbtech has operations in 11 countries and has offices in Stockholm, Atlanta, Frankfurt and London. 

i. Epstein, N.J et al. (2006). Assessing medication effects in the MTA study using neuropsychological outcomes. Journal of Child Psychology and Psychiatry, 47, 446-456.

ii. Vogt, C., & Shameli, A. (2011). Assessments for attention-deficit hyperactivity disorder: use of objective measurements The Psychiatrist, 35, 380-383.

iii. Vogt, C., & Williams, T. (2011). Early identification of stimulant treatment responders, partial Responders and non- responders using objective measures in children and adolescents with hyperkinetic disorder. Child and Adolescent Mental Health, 3, 144-149.

For further enquiries, please contact:

Carl Reuterskiöld, CEO of Qbtech, tel: +46-(0)-8-790-50-01, e-mail: ceo@qbtech.com

SOURCE Qbtech